The Maginot Line and AIDS vaccines

Medical Hypotheses

Volumn 48, Issue 6, 1997, Pages 527-529

  Stricker, R B ^a,c   Goldberg, B ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b Dinitrochlorobenzene Study Group   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACTIVE IMMUNIZATION; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION;

HUMAN IMMUNODEFICIENCY VIRUS; PRIMATES;

EID: 0030838062     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90124-9     Document Type: Article

References (24)

1. Mocci S, Coffman R L. Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4. J Immunol 1995; 154: 3779-3787.
2. Croft M, Swain S L. Recently activated naive CD4 T cell can help resting B cells, and can produce sufficient autocrine IL-4 to drive differentiation to secretion of T helper 2-type cytokines. J Immunol 1995; 154: 4269-4282.
3. Perez V L, Lederer J A, Lichtman A H, Abbas A K. Stability of Th1 and Th2 populations. Int Immunol 1995; 7: 869-875.
4. Romagnani S A. Biology of human Th1 and Th2 cells. J Clin Immunol 1995; 3: 121-129.
5. Pantaleo G, Fauci A S. New concepts in the immunopathogenesis of HIV infection Annu Rev Immunol 1995; 13: 487-512.
6. Clerici M, Shearer G M. A Th1-Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107-111.
7. Romagnani S, Maggi E, Del Prete G. An alternative view of the Th1/Th2 switch hypothesis in HIV infection. AIDS Res Hum Retroviruses 1994; 10: iii-ix.
8. Mosmann T R. Cytokine patterns during the progression to AIDS. Science 1994; 265: 193-194.
9. Levy J A. HIV research: A need to focus on the right target. Lancet 1995; 345: 1619-1621.
10. Schwartz D H. Potential pitfalls on the road to an effective HIV vaccine. Immunol Today 1994; 15: 54-57.
11. Heath S L, Tew J G, Tew J G, Szakal A K, Burton G F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995; 377: 740-744.
12. Salk J, Bretscher P A, Salk P L, Clerici M, Shearer G M. Protection from HIV infection or AIDS? Science 1993; 262: 1074-1076.
13. Tindle R W, Croft S, Herd K et al. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in mice in the absence of oil-based adjuvants. Clin Exp Immunol 1995; 101: 265-271.
14. Shearer G M, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996; 17: 21-24.
15. Striker R B, Elswood B F, Goldberg B et al. Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene (DNCB). J Am Acad Dermatol 1994; 31: 462-466.
16. Sato T, Maguire H C, Mastrangelo M J, Berd D. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin Immunol Immunopathol 1995; 74: 35-43.
17. Good M F. Harnessing cytotoxic T lymphocytes for vaccine design. Lancet 1995; 345: 999-1000.
18. Mountford A P, Anderson S, Watson R A. Induction of Th1 cell-mediated immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J Immunol 1996; 156: 4739-4745.
19. Arnon R, Horwitz R J. Synthetic peptides as vaccines. Curr Opin Immunol 1992; 4: 449-453.
20. Disis M L, Bernhard H, Shiota F M et al. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88: 202-210.
21. Fultz P N, Stricker R B, McClure H M, Anderson D C, Switzer W M, Horaist C. Humoral response to SIV/SMM infection in macaque and mangabey monkeys. J AIDS 1990; 3: 319-329.
22. Heeney J L. AIDS: A disease of impaired Th-cell renewal? Immunol Today 1995; 16: 515-520.
23. Villinger F, Folks T M, Lauro S et al. Immunological and virological studies of natural SIV infection of disease-resistant non-human primates. Immunol Lett 1996; 51: 59-68.
24. Kurth R, Norley S. Why don't the natural hosts of SIV develop simian AIDS? J NIH Res 1996; 8: 33-37.